BVS vs LH: fair value comparison
Bioventus Inc. and Labcorp Holdings Inc. · Updated 2026-09-12
BVS currently screens as overvalued while LH screens as fairly valued. Within Healthcare, LH currently sits closer to the top of our discount ranking. BVS carries the stronger quality grade.
| BVS | LH | |
|---|---|---|
| Verdict | Overvalued | Fairly valued |
| Last price | $13.67 | $311.54 |
| 12-month range | $6.56–$13.67 | $251.66–$327.61 |
| Sector rank | #89 of 113 Healthcare | #88 of 113 Healthcare |
| Quality grade | C | D |
| Leverage | Moderate | Moderate |
| Margin trend | Stable | Stable |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: BVS fair value analysis · LH fair value analysis